The EVERY Co has urged a court in Wisconsin to toss a lawsuit from Onego Bio seeking to invalidate one of EVERY's patents.

Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), ...

The collaboration between the University and CyanoCapture will focus on developing innovative methods for producing targeted ...

The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based ...

Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life ...

Vishal Mukund Sonje, Vaccine Manufacturing Lead, CEPI, talks about the challenges that arise in the manufacturing of vaccines ...

Protalix and Chiesi Global Rare Diseases, its partner in "the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based ...

If approved, the drug could become the first treatment for haemorrhagic stroke outside of surgical intervention.

From October 28th to 30th, Kexing Biopharm participated in CPHI Frankfurt 2025, one of the world's most influential pharmaceutical exhibitions, presenting its key product portfolio and international ...

Research and Development Expenses -- $9.6 million in the third quarter of 2025, down from $12.3 million in Q3 2024, due to ...

The large molecule drug substance CDMO market is projected to grow at a CAGR of approximately 9% over the forecast period. This growth is primarily driven by the rising demand for biologics and ...

Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald ...